LiverLearning®: 2017 Webinar: Controversy Regarding HCV Treatment and HCC Recurrence
- Read more about LiverLearning®: 2017 Webinar: Controversy Regarding HCV Treatment and HCC Recurrence
This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.Michael D. Leise (Moderator) Dr.